Company Overview of NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, discovers and develops transformational biologics for the treatment of cardio-metabolic diseases, hepatic diseases, and cancers. It offers NGM282, a phase 2 clinical development products that is used for the treatment of gastric bypass surgery on metabolic and bile acid-related diseases. The company also develops novel drug candidates for the treatment of Type 2 diabetes and obesity. In addition, it offers various drug discovery programs that include enteroendocrine cells, beta-cell regeneration, and intestinal microbiome programs. The company has strategic partnerships with MedImmune/AstraZeneca, Daiichi Sankyo, and JDRF. NGM Biopha...
630 Gateway Boulevard
South San Francisco, CA 94080-7014
Founded in 2007
Key Executives for NGM Biopharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, Chief Scientific Officer and Director
Chief Operating Officer and Vice President
Compensation as of Fiscal Year 2015.
NGM Biopharmaceuticals, Inc. Key Developments
NGM Biopharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 through Oct-21-2015
Sep 21 15
NGM Biopharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 through Oct-21-2015. Venue: Parc 55 Hotel, San Francisco, California, United States. Presentation Date & Speakers: Oct-20-2015, Jeff Jonker, President. Oct-21-2015, David Woodhouse, Chief Financial Officer.
NGM Biopharmaceuticals, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM
Apr 16 15
NGM Biopharmaceuticals, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Jeff Jonker, President.
NGM Biopharmaceuticals, Inc. Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282
Mar 24 15
NGM Biopharmaceuticals, Inc. reported positive results from a Phase 2 trial of NGM282 in patients with primary biliary cirrhosis (PBC). NGM282, an engineered protein variant of the human hormone FGF19, demonstrated statistically significant, dose-dependent and clinically meaningful reductions in alkaline phosphatase (ALP), a primary indicator of disease activity, as well as substantial reductions in 7-Hydroxy-4-cholesten-3-one (C4), a marker of bile acid synthesis. These data suggested that NGM282 is a potent regulator of bile acid synthesis. The study was a double blind, placebo-controlled trial in 45 patients randomized 1:1:1 to daily injections of 0.3 mg or 3 mg doses of NGM282 or placebo. Study subjects had a confirmed PBC diagnosis with an inadequate response to ursodeoxycholic acid (UDCA), the current standard of care, defined as an elevated ALP level greater than 1.67 times the upper limit of normal while on therapeutic doses of UDCA for at least 12 months. All subjects continued with UDCA treatment during the study. Patients with pruritus, hyperlipidemia and other comorbidities commonly seen in PBC were allowed to enroll in the study. Data from the trial demonstrated a statistically significant and clinically meaningful percentage reduction in ALP from baseline to day 28 in both NGM282 treatment arms (0.3 mg = -15.8%, p-value = 0.009; 3 mg = -19.2%, p-value = 0.003). Significant reductions of other key markers of liver injury, such as ALT and AST, were also observed for both NGM282 treatment groups. Importantly, NGM282 did not exacerbate pruritus, which is a symptom frequently experienced by many PBC patients that substantially impacts quality of life. More than 50% of study subjects had pruritus at baseline, which was balanced across the three groups. All subjects with pruritus at baseline treated with 3 mg of NGM282 had either an improvement or no worsening of their pruritus during the study. Two subjects without pruritus at baseline, one in each treatment arm, presented with mild, transient pruritus during the study period. However, the overall study assessment demonstrated that there was no significant evidence of drug-induced pruritus in any study arm. NGM282 had a favorable safety and tolerability profile with no identified safety signals. Most adverse events were mild, with a single serious adverse event during the study period that was deemed unrelated to treatment by the investigator. The most common adverse events were mild headache and mild lower gastrointestinal (GI) symptoms (predominantly diarrhea and loose stools). The lower GI symptoms were observed in 21% of the 0.3 mg and 43% of the 3 mg cohorts, compared to 13% of the placebo group. Mild injection site reactions (predominantly erythema or redness) were also observed more frequently with NGM282. There was no evidence of an immunogenic response to NGM282 during or after the treatment period. All lipid parameters and triglycerides remained stable during the treatment period.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 23, 2015